Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 7/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176192 | 0.87 | AR (0.50) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL16946783 | 0.87 | AR (0.51) | ARPGRCYP2C19ABCB11ALB | |
| SCHEMBL2633009 | 0.85 | AR (0.50) | AR | |
| SCHEMBL16946784 | 0.85 | AR (0.52) | AR | |
| SCHEMBL16823496 | 0.84 | TAS2R14 (0.53) | AR | |
| SCHEMBL16855264 | 0.83 | TAS2R14 (0.51) | AR | |
| SCHEMBL17651741 | 0.82 | AR (0.50) | AR | |
| SCHEMBL21048280 | 0.82 | AR (0.53) | AR | |
| SCHEMBL30901510 | 0.82 | AR (0.53) | AR | |
| SCHEMBL29880411 | 0.82 | AR (0.50) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023275091-A1 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | Química Sintética, S.A. (ES) | 2023-01-05 | — | — | WO | disclosed |
| EP-3129356-B1 | A PROCESS FOR PRODUCING ENZALUTAMIDE | ZENTIVA KS (CZ) | 2020-06-03 | — | — | EP | disclosed |
| US-10626091-B2 | Process for the preparation of enzalutamide | LAURUS LABS LIMITED (IN) | 2020-04-21 | — | — | US | disclosed |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2019-05-02 | — | — | US | disclosed |
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS LIMITED (IN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016051423-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2016-04-07 | — | — | WO | disclosed |
| WO-2015154730-A1 | A PROCESS FOR PRODUCING ENZALUTAMIDE | ZENTIVA, K.S. (CZ) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313662-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | L3MBTL1 4172/4885AR 8/4885PGR 2547/4885 |
| US-20190127332-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | KLK4, KLK5, KLK1 | L3MBTL1 4126/4885AR 8/4885PGR 2237/4885 |
| US-10626091-B2 | Process for the preparation of enzalutamide | KLK4, KLK5, KLK1 | L3MBTL1 4126/4885AR 8/4885PGR 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.